KRAS and familial pancreatic carcinoma: To more comprehensively delineate the impact of long-term ERK/MAPK blockade on signaling networks, we applied reverse phase protein array (RPPA)32 to serially profile a KRAS-mutant pancreatic cancer cell line exposed to dual-mechanism ERK inhibition over a time course ranging from one hour to eight weeks (Fig. 1d, Supplementary Table 1).